Reason for request

Inclusion on list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication “Treatment of schizophrenia in adolescents aged 15 years and older”.


Clinical Benefit


The actual benefit of these proprietary medicinal products in the extension of indication is substantial.

Clinical Added Value

no clinical added value

Given the absence of a comparison with an active comparator and the inadequate duration of evaluation, and pending the availability of controlled data over a treatment period of at least 6 months, ABILIFY does not provide an improvement in actual benefit in the management of schizophrenia in adolescents.

Contact Us

Évaluation des médicaments

See also